The accumulation of ␤-amyloid protein (A␤) is a key risk factor in the development of Alzheimer's disease. The ovarian sex steroid hormones 17␤-estradiol (E 2 ) and progesterone (P 4 ) have been shown to regulate A␤ accumulation, although the underlying mechanism(s) remain to be fully elucidated. In this study, we investigate the effects of E 2 and P 4 treatment on the expression levels of A␤ clearance factors including insulin-degrading enzyme, neprilysin, endothelin-converting enzyme 1 and 2, angiotensin-converting enzyme, and transthyretin, both in primary neuron cultures and female rat brains. Our results show that E 2 and P 4 affect the expression levels of several A␤ clearance factors in dose-and time-dependent manners. Most notably, expression of insulindegrading enzyme is significantly increased by both hormones in cultured neurons and in vivo and is inversely associated with the soluble A␤ levels in vivo. These findings further define sex steroid hormone actions involved in regulation of A␤, a relationship potentially important to therapeutic approaches aimed at reducing risk of Alzheimer's disease. (Endocrinology 153: 5467-5479, 2012) A lzheimer's disease (AD) is an age-related neurodegenerative disorder that is the leading cause of dementia. Despite the strong association between increasing age and AD risk (1), the changes underlying this relationship are not well defined. One normal age change that has been identified as an AD risk factor is the depletion of sex steroid hormones (2). The relatively abrupt reduction in estrogens and progesterone (P 4 ) at menopause has been theorized to contribute to the increased prevalence (3) and incidence (4, 5) of AD and worsened pathological (6) and clinical presentations (7, 8) of the disease in women. Among postmenopausal women, those with AD are characterized by lower 17␤-estradiol (E 2 ) levels in plasma (9), brain (10, 11), and cerebrospinal fluid (12). Further, estrogen-based hormone therapy in postmenopausal women is associated with a reduced risk of AD (13, 14), although this field remains controversial (15, 16) and may require initiation of treatment in middle age (17).
A
lzheimer's disease (AD) is an age-related neurodegenerative disorder that is the leading cause of dementia. Despite the strong association between increasing age and AD risk (1) , the changes underlying this relationship are not well defined. One normal age change that has been identified as an AD risk factor is the depletion of sex steroid hormones (2) . The relatively abrupt reduction in estrogens and progesterone (P 4 ) at menopause has been theorized to contribute to the increased prevalence (3) and incidence (4, 5) of AD and worsened pathological (6) and clinical presentations (7, 8) of the disease in women. Among postmenopausal women, those with AD are characterized by lower 17␤-estradiol (E 2 ) levels in plasma (9), brain (10, 11) , and cerebrospinal fluid (12) . Further, estrogen-based hormone therapy in postmenopausal women is associated with a reduced risk of AD (13, 14) , although this field remains controversial (15, 16) and may require initiation of treatment in middle age (17) .
How estrogens and perhaps P 4 alter AD risk is not known. The critical molecule in initiating and driving AD neuropathology is widely hypothesized to be ␤-amyloid protein (A␤), a peptide that accumulates predominantly in hippocampus and select cerebrocortical regions of brain forming toxic oligomers and extracellular deposits (18) . Increasing evidence suggests that sex steroid hormones are significant regulators of A␤ levels. For example, ovariectomy-induced depletion of E 2 and P 4 can result in elevated A␤ levels in wild-type rodents (19) and transgenic mouse models of AD (11, 20) , an effect prevented by treatment with E 2 (19, 21) and, in some cases, P 4 (22) . Peripheral manipulations of E 2 do not affect A␤ levels in some animal models (23) , suggesting maintained neural levels of E 2 by brain-derived mechanisms (11) . Normally, A␤ accumulation is prevented by a tightly regulated balance between its production and clearance. Prior work indicates that E 2 may reduce A␤ production in part by regulating the processing and/or trafficking of its parent protein, amyloid precursor protein (24, 25) .
Less well understood are the roles of E 2 and P 4 in regulating the clearance of A␤. An important clearance mechanism is enzyme-mediated degradation of A␤. A␤-degrading enzymes are expressed in neurons and are present in the hippocampal and cortical regions of the brain (26) . Proteases implicated in A␤ degradation include insulin-degrading enzyme (IDE), neprilysin (NEP), endothelin-converting enzymes-1 (ECE1) and -2 (ECE2), and angiotensin-converting enzyme (ACE) (27) . IDE is the most abundant secreted A␤-degrading enzyme and is significantly involved in degradation of monomeric A␤ (28, 29) . Genetic deletion of IDE results in elevated brain levels of A␤ (30) , whereas IDE overexpression reduces A␤ deposition (28, 29, 31) . NEP plays an important role in the clearance of A␤ (32, 33) but, unlike IDE, NEP is able to degrade oligomeric A␤ (34) . Recent evidence suggests NEP may be particularly important to AD because its expression is inversely correlated with levels of both A␤ and cognitive impairment (35) . Although IDE and NEP are often regarded as the key A␤-degrading enzymes, there is compelling evidence that several other factors also may significantly contribute to A␤ degradation. Both ECE1 and ECE2 have been identified as A␤-cleaving enzymes capable of reducing A␤ levels in in vitro, cell culture, and/or animal paradigms (36, 37) . ACE has also been shown to degrade secreted A␤, and inhibition of ACE activity by either genetic or pharmacological approaches leads to elevated A␤ (38, 39) . In addition to A␤-degrading enzymes, A␤ clearance can be facilitated by other factors such as transthyretin (TTR), which binds A␤ and can lower A␤ burden in transgenic mouse models of AD (26, 40) .
To further define the relationship between ovarian hormones and regulation of A␤, we investigated the effects of E 2 and P 4 on the expression of IDE, NEP, ECE1, ECE2, ACE, and TTR. Three complementary experimental paradigms were used. First, we performed initial characterization and mechanistic investigation using short-term E 2 and P 4 treatments in primary neuron cultures. Next, we examined the effects of short-term E 2 and P 4 treatments in vivo to evaluate the extent to which culture observations extrapolate to the organism level. Finally, we performed long-term studies in vivo to model the effects of extended treatment regimens associated with hormone therapies. Importantly, because hormone therapies in postmenopausal women typically involve combinations of estrogens and progestogens, our long-term in vivo studies compared both individual and combined actions of E 2 and P 4 . In addition, we evaluated brain levels of soluble A␤ in hormone-treated rats to provide insight into the relationships between E 2 and P 4 regulation of the A␤ clearance factors and the corresponding accumulation of A␤.
Materials and Methods

Materials
E 2 was purchased from Steraloids, Inc. (Newport, RI) and progesterone (P 4 ) was purchased from Acros Organics USA (Morris Plains, NJ). Antiestrogen ICI 182,780, estrogen receptor (ER) ␣-agonist propylpyrazole triol (PPT), and ER␤ agonist 2,3-bis(4-hydroxyphenyl) propionitrile (DPN) were acquired from Tocris (Ellisville, MO). Progesterone receptor (PR) antagonists RU 486 was purchased from Sigma-Aldrich (St. Louis, MO), and Org 31710 was generously provided by N.V. Organon (Oss, The Netherlands). Stock solutions of all compounds were prepared in 100% ethanol.
Animals
For cell culture studies, timed-pregnant female Sprague Dawley rats (Harlan Laboratories, Inc., Livermore, CA) were killed via CO 2 inhalation, and the pups were harvested for preparation of neuronal cultures. For in vivo studies, female Sprague Dawley rats were purchased either bilaterally ovariectomized (OVX) or sham-OVX at 3 months of age (Harlan Laboratories, Inc.). All animals were housed individually with ad libitum access to food and water under a 12 h-light, 12-h dark light cycle. All animal procedures were conducted under a protocol that was approved by the University of Southern California and in accordance with National Institute of Health standards.
Primary neuron culture
Neuron-enriched, primary rat cerebrocortical cultures (ϳ95% neuronal as determined by positive immunoreactivity with the neuron-specific antibody NeuN) were prepared with some modifications of a previously described protocol (41) . Briefly, cerebral cortices were dissected from gestational day 17-18 Sprague Dawley rat pups (n Ն 6 pups per preparation). Cortices were enzymatically dissociated using 0.25% trypsin at 37 C for 5 min. The reaction was quenched using two volumes of DMEM (American Type Culture Collection; Manassas, VA) containing 10% (vol/vol) fetal bovine serum. The tissue was centrifuged at 200 ϫ g and the pellet was resuspended. The resultant cell suspension was mechanically dissociated using flame-polished glass Pasteur pipettes and then filtered through a 40-m cell strainer (Falcon, Franklin Lakes, NJ). The single-cell suspension was diluted using DMEM containing N2 supplements (without P 4 ) and plated onto poly-L-lysine-coated multiwell plates at a final density of 8 ϫ 10 5 cells/cm 2 . Cultures were maintained at 37 C in a humidified incubator supplemented with 5% CO 2 . All experiments were started after 1-2 d in vitro and were repeated in three to five independent culture preparations. Cultures were treated with ethanol vehicle or various combinations of E 2 , P 4 , and ER and PR agonists and antagonists that were diluted from ethanol stock solutions with culture medium to yield a final ethanol concentration of Ն0.01%.
Hormone treatments in animals
In the short-term experiment, rats were randomly assigned to four groups (n ϭ 7/group): sham OVX ϩ vehicle (Sham); OVX ϩ vehicle (OVX); OVX ϩ 17␤-estradiol (OVXϩE 2 ); and OVX ϩ progesterone (OVXϩP4). Treatments were administered via two injections, the first injection 7 d after sham OVX or OVX procedure and the second injection 24 h later. Injections contained either vehicle (100 l canola oil), 10 g E 2 (100 l of 100 g/ml E 2 in canola oil), or 500 g P 4 (100 l of 5 mg/ml P 4 in canola oil), doses previously demonstrated to yield physiological levels of E 2 and P 4 in OVX rats (42) . Tissues were collected 24 h after the second injection.
For the long-term experiment, rats were either sham OVX (Sham, n ϭ 8) or OVX. OVX rats were randomly assigned to one of six groups (n ϭ 8/group): placebo (OVX), continuous E 2 (OVXϩE 2 ), continuous P 4 (OVXϩP4 cont ), cyclic P 4 (OVXϩP4 cyc ), continuous E 2 with continuous P 4 (OVXϩE 2 ϩP4 cont ), or continuous E 2 with cyclic P 4 (OVXϩE 2 ϩP4 cyc ). Rats were treated with two consecutive 30-d cycles of hormone treatment (60 d total) initiated 7 d post-OVX and delivered via slow-release sc implants (Innovative Research America, Sarasota, FL). On d 0, Sham and OVX groups were implanted with placebo pellets; each E 2 -treated rat was implanted with a 0.72-mg E 2 90-d release pellet; each continuous P 4 -treated rat was implanted with a 450-mg P 4 90-d release pellet; each cyclic P 4 rat was implanted with one 50-mg P 4 10-d release pellet at d 20 and a second pellet at d 50. The efficacy of this cyclic P 4 regimen has been demonstrated previously (22) . After the treatment period, the rats were killed, and each brain was rapidly dissected and bisected midsagitally. The hippocampus from one hemisphere was snap frozen for use in RNA and protein extractions, and the other entire hemisphere was snap frozen for use in ␤-amyloid ELISA. Uteri were dissected, blotted, and weighed as a bioassay of estrogen levels.
RT-PCR and quantitative PCR
For RNA extractions in all experiments, treated cells and tissues were lysed using TRIzol reagent (Invitrogen, Carlsbad, CA) and processed for total RNA extraction as per manufacturer's protocol. Purified RNA (1-2 g) was used for reverse transcription using the Superscript First strand synthesis system (Invitrogen) as described previously (43) , and the resulting cDNA was used for both standard PCR and real-time quantitative PCR. Quantitative PCR was carried out using DNA Engine Opticon 2 continuous fluorescence detector (MJ Research, Inc., Waltham, MA). The amplification efficiency was estimated from the standard curve for each gene. Relative quantification of mRNA levels from various treated samples was determined by the ⌬⌬Ct method (44) . The following primer pairs were used. IDE: forward, 5Ј-GGAAGCGTTCGCCGAGATCGCA-3Ј; reverse, 5Ј-TCTGAATCGACAGCGTTCAC-3Ј; NEP: forward; 5Ј-CATTGAACTATGGGGGCATC-3Ј; reverse, 5Ј-CCTGAAATT-GCCAGGACTGT-3Ј; ECE1: forward, 5Ј-GAGCTGACTCAT-GCTTTC-3Ј; reverse, 5Ј-CAGCTCCGTTCTTCTTTA-3Ј; ECE2: forward, 5Ј-AGAAAGTTCTCGCTGCCT-3Ј; reverse, 5Ј-AGTG-GCGACAACAAGAAA-3Ј; ACE: forward, 5Ј-GAGCCATCCTTC-CCTTTT-3Ј; reverse, 5Ј-GGCTGCAGCTCCTGGTAT-3Ј; TTR: forward, 5Ј-GGCTCACCACAGATGAGA-3Ј; reverse, 5Ј-ACA-AATGGGAGCTACTGC-3Ј; ␤-actin: forward, 5Ј-AGCCATG-TACGTAGCCATCC-3Ј; reverse, 5Ј-CTCTCAGCTGTGGTG-GTGAA-3Ј.
Western blots
For all experiments involving protein analysis by immunoblotting, treated cultures and tissues were lysed using a reducing sample buffer (62.5 mM Tris-HCl, 1% sodium dodecyl sulfate, 2.5% glycerol, 0.5% 2-␤-mercaptoethanol), boiled for 5 min at 100 C, and centrifuged at 13,000 ϫ g for 10 min. The resultant supernatants were used for Western blot analysis using a standard protocol previously described (41) . Briefly, equal sample amounts were electrophoresed in 10% polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Millipore Corp., Medford, MA) at constant 100 V for 1 h. The membranes were rinsed in blocking solution (5% BSA in 10 mM Tris, 100 mM NaCl, 0.1% Tween, pH 7.4) for 1 h at room temperature (RT), followed by incubation with primary antibody (␣-IDE, Abcam; San Francisco, CA) diluted in blocking solution for 1 h at RT. The membranes were then incubated with corresponding horseradish peroxidase-conjugated secondary antibody for 1 h at RT and detected using ECL (Amersham; Arlington Heights, IL).
␤-Amyloid ELISA
Brain levels of soluble A␤1-42 were determined by ELISA with modifications of a previously described protocol (45) . In brief, hemi-brains were processed for A␤ ELISA after extracting soluble protein by homogenization in ice-cold DEA buffer (0.2% diethylamine, 50 mM NaCl; 1 ml/200 mg tissue) with complete protease inhibitor cocktail (Amresco, Solon, OH) using an AHS200 PowerMax polytron. Homogenates were centrifuged at 20,800 ϫ g at 4 C for 30 min, after which the supernatants were collected and neutralized (one tenth volume of 0.5 M Tris-HCl, pH 6.2). Levels of soluble A␤ were then measured via sandwich capture ELISA using a Colorimetric BetaMark ␤-Amyloid x-42 ELISA kit (Covance Laboratories, Inc., Princeton, NJ).
Statistical analyses
Raw data from all experiments were assessed by ANOVA using GraphPad Prism (version 5.0; GraphPad Software, Inc., San Diego, CA). For analyses showing significant main effects, between-groups comparisons were made using the Tukey honestly significant difference (HSD) test. Effects with P Ͻ 0.05 were considered significant.
Results
E 2 and P 4 regulate mRNA levels of A␤ clearance factors in primary neuron cultures
To investigate the effects of E 2 on expression levels of factors involved in A␤ degradation and clearance, primary neuron cultures were treated for 24 h with increasing concentrations of E 2 (0 -100 nM). RNA was isolated from cultures and processed for PCR using specific primers for IDE, NEP, ACE, ECE1, ECE2, and TTR. Our results qualitatively and quantitatively show that E 2 induced a dose-dependent increase in mRNA levels of IDE [F (5, 12) ϭ 6.1, P Ͻ 0.01], significantly decreased expression of ACE [F (5, 12) ϭ 6.1, P Ͻ 0.01] and ECE2 [F (5, 12) ϭ 14.1, P Ͻ 0.001], and had no significant effect on mRNA levels of NEP, ECE, and tran-sthyretin (TTR) (Fig. 1, A and B ). E 2 effects were statistically significant at the 10 nM and 100 nM concentrations. To investigate the time courses of E 2 regulatory actions, we treated neuron cultures with 10 nM E 2 for increasing periods of time up to 24 h. The E 2 -induced increase in IDE [F (5, 12) ϭ 22.4, P Ͻ 0.001], and decreases in ACE [F (5, 12) ϭ 12.7, P Ͻ 0.01], and ECE2 [F (5, 12) ϭ 11.1, P Ͻ 0.01], became apparent within 8 h of treatment and statistically significant by 16 h (Fig. 1,  C and D) .
In parallel experiments, we similarly evaluated the effects of P 4 on expression of IDE, NEP, ACE, ECE1, ECE2, and TTR. Treatment of neuron cultures for 24 h with P 4 concentrations of 3 nM, 30 nM, and 300 nM resulted in statistically significant, approximately 2-fold increases of IDE [F (5, 12) (Fig. 2, C and D) .
The role of hormone receptors in E 2 and P 4 regulation of A␤ clearance factors
To investigate the contributions of estrogen receptors (ER) to the observed E 2 regulation of IDE, ACE, and ECE2 expression, we first evaluated the effect of the antiestrogen ICI 182,780 (46) . Neuron cultures were pretreated with 1 M ICI 182,780 for 1 h followed by 10 nM E 2 or vehicle treatments for 24 h. Cultures were harvested for RNA followed by qualitative and quantitative PCR. Our results demonstrate ICI 182,780 completely blocks the E 2 -mediated increase in IDE mRNA, suggesting an ER-dependent mechanism (Fig. 3, A and B) . In contrast, the E 2 -induced downregulation of ACE and ECE2 mRNA levels remained unchanged in the presence of ICI 182,780, suggesting that these effects occur via either ER-independent pathways or nongenomic mechanisms that are ER dependent but insensitive to ICI 182,780 (Fig. 3, A and B) . To gain further insight into the role of ER, we treated neuron cultures for 24 h with increasing concentrations (0 -100 nM) of PPT (47) (Fig. 3, C-F) .
To evaluate the role of PR on P 4 -induced regulation of IDE, ACE, and TTR mRNA, we used the PR antagonists RU486 (49) and Org 31710 (50) . Neuron cultures were pretreated with vehicle, 50 nM RU486, or 1 M Org 31710 followed by 16-h exposure to 30 nM P 4 and then harvested for RNA isolation. Our PCR results show that P 4 -induced increases in mRNA levels of IDE and ACE mRNA levels were not significantly altered in the presence of the PR antagonists. Conversely, both RU486 and Org 31710 effectively blocked the up-regulation of TTR mRNA levels by P 4 (Fig. 3 , G and H).
E 2 and P 4 regulate levels of A␤ clearance factors in rat brain
As an initial step to determine whether significant neuronal culture observations extrapolate to brain, we examined the effects of short-term exposures of E 2 and P 4 on mRNA levels of IDE, ACE, ECE2, and TTR in female Representative agarose gel of RT-PCR products show relative changes in mRNA levels of the A␤ clearance factors TTR, IDE, ACE, ECE1, NEP, and ECE2 induced by 24-h exposure to 0 -100 nM E 2 . ␤-Actin was used as an internal control. B, The levels of A␤ clearance factors after treatment with increasing E 2 concentrations were also determined quantitatively using real-time PCR. Data show the mean (ϮSEM) expression levels, relative to vehicle-treated controls after normalizing with corresponding values of ␤-actin. Representative agarose gel of RT-PCR (C) and quantitative graph from real-time PCR (D) show changes in levels of IDE, ACE, and ECE2 mRNA induced by 0 -24 h exposure to 10 nM E 2 . Statistical significance is based on analysis of pooled raw data using the Tukey HSD. *, P Յ 0.05 relative to corresponding vehicle-treated control group. rat brain. Young adult, female Sprague Dawley rats were sham OVX or OVX to deplete endogenous E 2 and P 4 . One week after surgery, rats were injected twice with vehicle (canola oil), 10 g E 2 , or 500 g P 4 , once at time 0 h and again 24 h later. Rats were killed 24 h after the second injection, at which time the brains were immediately collected, frontal cortices were dissected, and RNA was isolated for PCR analyses. Analysis of uterine weight confirmed efficacy of the OVX procedure in depleting endogenous estrogens and the efficacy of E 2 treatment in restoring uterine mass (Table 1) . We observed statistically significant effects of the hormone manipulations on mRNA levels of IDE [F (3, 8) ϭ 11.0, P Ͻ 0.01], ACE [F (3, 8) ϭ 4.9, P ϭ 0.03], and ECE2 [F (3, 8) ϭ 9.9, P Ͻ 0.01], but not on TTR levels [F (3, 8) ϭ 0.6, P ϭ 0.66]. In comparison with sham controls, the OVX group showed nonsignificant trends of reduced IDE mRNA and increased ACE mRNA (Fig 4, A and B) and a statistically significant increase in ECE2 mRNA (Fig. 4, A, C, and D) . The OVXϩE 2 group showed significantly elevated levels of IDE and reduced levels of ACE and ECE2 relative to the OVX group (Fig. 4, A-D) . Similarly, the OVXϩP 4 group was associated with significantly increased IDE and decreased ECE2 mRNA in comparison with the OVX group, but P 4 treatment exhibited no significant effect on ACE levels (Fig. 4,  A-D) .
We next evaluated the individual and combined effects of E 2 and P4 over an extended treatment period. Consistent with our previously established protocol (22), we exposed OVX female rats to two consecutive, 30-d cycles of hormone treatment consisting of continuous E 2 , continuous P 4 , cyclic P 4 (10 d/cycle), or combinations of E 2 with continuous or cyclic P 4 . As with the short-term experiment, uterine weights were significantly reduced by OVX, an effect reversed in OVX groups treated with E 2 ( Table  1) . Expression of IDE mRNA significantly differed across groups [F (6, 21) ϭ 15.3, P Ͻ 0.001]. Neocortical IDE mRNA was significantly decreased in the OVX group, an effect that was prevented by treatment of OVX rats with continuous E 2 (OVXϩE 2 ) and cyclic P 4 (OVXϩP cyc ) but not by continuous P 4 (OVXϩP4 cont ). Notably, the effect of combining E 2 and P 4 depended upon the delivery regimen of P 4 . The up-regulation of IDE mRNA by continuous E 2 was blocked by cotreatment with continuous P 4
FIG. 2. P 4 regulates expression of A␤ clearance factors in a dose-and time-dependent manner. A, Representative agarose gel of RT-PCR products
show relative changes in mRNA levels of the A␤ clearance factors TTR, IDE, ACE, ECE1, NEP, and ECE2 induced by 16-h exposure to 0 -300 nM P 4 . ␤-Actin was used as an internal control. B, The levels of A␤ clearance factors after treatment with increasing P 4 concentrations were also determined quantitatively using real-time PCR. Data show the mean (ϮSEM) expression levels, relative to vehicle-treated controls after normalizing with corresponding values of ␤-actin. Representative agarose gel (C) and quantitative graph from real-time PCR (D) show changes in levels of IDE, ACE, and TTR mRNA induced by 0 -24 h exposure to 30 nM P 4 . Statistical significance is based on analysis of pooled raw data using the Tukey HSD. *, P Յ 0.05 relative to corresponding vehicle-treated control group. (Fig. 5 , A and C). Both P 4 treatments significantly inhibited the effect of E 2 on ACE mRNA (Fig. 5, A and C) . There was no statistically significant main effect of treatment group on ECE2 mRNA levels [F (6, 14) ϭ 1.5, P ϭ 0.24] (Fig. 5, A and D) . Levels of TTR mRNA levels significantly differed across groups [F (6, 21) ϭ 5.5, P Ͻ 0.01]. Although there were no significant effects of OVX or E 2 treatment, there was a modest increase in TTR mRNA in the OVXϩP4 cyc group relative to both Sham and OVX groups (Fig. 5 , A and E).
E 2 and P 4 regulate IDE protein in vitro and in vivo
The only A␤ clearance factor that was positively regulated at the mRNA level by E 2 and/or P 4 across all of our cell culture and in vivo paradigms was IDE. To confirm that the observed up-regulation of IDE mRNA by E 2 and P 4 yielded increased protein levels of IDE, we conducted Western blots in both cell culture and brain samples. In neuronal cultures, E 2 increased IDE protein in a dosedependent manner by up to 2-fold with statistically significant effects apparent at 0.1 nM (Fig. 6, A and F) [F (5, 12) ϭ 92.6, P Ͻ 0.001]. In cultures treated with 10 nM E 2 , significant increases in IDE protein occurred within 8 h and were retained across the 48-h experimental period [F (4, 10) ϭ 142.1, P Ͻ 0.001] (Fig. 6, B and G) . Similarly, P 4 induced increased IDE protein with significant effects observed between concentrations of 0.3 nM and 300 nM [F (5,12) ϭ 33.4, P Ͻ 0.001] (Fig. 6, C and H) and at exposure times between 8 h and 48 h [F (4, 10) ϭ 23.9, P Ͻ 0.001] (Fig. 6, D and I) . In female rats, IDE levels were significantly affected by treatment [F (3, 8) ϭ 20.4, P Ͻ 0.001]. We observed that the OVX group exhibited a nonsignificant trend of reduced IDE protein relative to the Sham group. Short-term treatment of OVX rats with E 2 (OVXϩE 2 ) or P 4 (OVXϩP 4 ) yielded significant increases in IDE protein levels, with the OVXϩE 2 group increasing IDE levels significantly higher than the Sham group (Fig.  6, E and J) .
Long-term regulation of soluble A␤ levels by E 2 and P 4 The significant positive regulation of the A␤ degrading enzyme IDE by both E 2 and P 4 across culture and in vivo paradigms suggests a possible role in regulating brain levels of A␤. To begin investigating this possibility, we homogenized one hemi-brain from each of the rats in the extended hormone treatment experiment to analyze soluble A␤ levels by ELISA. Our results indicate a statistically significant effect of treatment on A␤42 levels [F (3, 28) ϭ 3.3, P ϭ 0.01]. Ovarian hormone depletion associated with OVX resulted in a significant, approximately 2-fold increase in A␤ that was largely prevented by continuous E 2 treatment (OVXϩE 2 ) (Fig. 7) . Treatment with P 4 alone delivered either continuously (OVXϩP4 cont ) or cyclically (OVXϩP4 cyc ) did not significantly lower A␤ levels relative to the OVX group. Interestingly, the regimen of cyclic P 4 in combination with E 2 (OVXϩE2ϩP4 cyc ) showed the lowest A␤42 levels.
Discussion
Although there are no definitive approaches for preventing and treating AD, clinical studies have demonstrated that the risk of AD in women can be significantly reduced by hormone therapy. Because accumulation of A␤ is widely theorized to initiate AD pathogenesis (51), optimizing hormone therapy will likely require thorough understanding of how estrogens and progestagens regulate A␤ accumulation. Prior work has clearly linked E 2 with regulation of A␤ production by affecting APP metabolism and trafficking (52) . Recent work has demonstrated that E 2 and P 4 may also play a role in A␤ clearance (2). Our results suggest that E 2 and P 4 are able to affect mRNA expression of some but not all A␤ clearance factors. Most notably, data in neuron cultures show that E 2 affects IDE, ACE, and ECE2 mRNA in dose-and time-dependent manners whereas P 4 regulates the expression levels of IDE, ACE, and TTR mRNA. In rat brain, both E 2 and P 4 are also shown to regulate IDE expression. Importantly, we also assess the relationship of expression changes 
with endogenous soluble brain levels of A␤, demonstrating an inverse association between the levels of IDE and soluble A␤. Our data demonstrate that E 2 regulates expression of several factors involved in A␤ clearance. The most robust effect across paradigms was the E 2 -induced increase in IDE expression, which was observed at both the mRNA and protein levels. The data show that the approximately 2-fold increase in IDE mRNA is ER dependent because it is blocked by an ER antagonist but mimicked by agonists for both ER␣ and ER␤. This observation is consistent with the finding that uterine IDE level and activity decrease during low E 2 phase and increase during high E 2 phase of the estrous cycle (53) . In addition, a recent independent study done by our group found that E 2 increased neuronal IDE expression in a mouse model of AD (54) .
In contrast to increasing IDE expression, we observed that E 2 did not alter or reduce expression of several other A␤ clearance factors. E 2 significantly decreased expression of ACE mRNA in neuron culture as well as in rat brain. This observation is consistent with several prior studies showing that E 2 reduces ACE levels in various tissues, including heart, lung, kidney, and brain (55) (56) (57) (58) . Similar results have been obtained in studies of postmenopausal women in which estrogen-based hormone therapy is associated with decreased ACE (59, 60) . In addition, we found that E 2 decreased ECE2 mRNA expression but had no significant effect on ECE1 transcript levels. E 2 regulation of ECE1 and ECE2 in brain has not been previously reported, but these enzymes are known to be regulated by sex steroid hormones (61) with E 2 shown to reduce ECE1 expression (62) . We observed no significant effect of E 2 treatment on either NEP or TTR mRNA expression. These data are in contrast to some prior reports. In the case of NEP, E 2 has been linked to increased expression in uterus (63) as well as in rat brain and a neuroblastoma cell line (64 -66) . E 2 is also associated with increased TTR expression in choroid plexus (67, 68) and in an AD transgenic mouse model (69) . The reason for the disparity in findings is unclear but may reflect paradigm differences. For example, because neurons are not fully differentiated in our culture paradigm, it is possible that qualitatively different hormone responses could be observed in neurons with an adult phenotype. Because IDE is the only A␤ clearance factor positively regulated by E 2 in our models, it appears to be the strongest candidate for contributing to the established ability of E 2 to reduce A␤ levels.
Although recent evidence indicates a role for P 4 (22) and P 4 metabolites (70, 71) in reducing A␤, there has been limited investigation of its potential regulation of A␤ clearance factors. Our neuron culture data show that P 4 increases by approximately 2-fold the mRNA levels of IDE, ACE, and TTR but does not significantly alter expression of NEP, ECE1, and ECE2 mRNA. Upon short- term and extended P4 exposure in vivo, IDE mRNA continued to exhibit strong up-regulation by P 4 but TTR mRNA was only modestly increased and ACE expression was not significantly affected. This incomplete concordance in findings between in vitro and in vivo paradigms suggests that although P 4 and E 2 have the potential to regulate numerous genes in simple culture systems, only a subset of these effects are manifested at significant levels in vivo owing to the influence of multiple tissue-specific and systems-wide interactions. The lack of significant P 4 regulation of ACE mRNA in vivo is consistent with a prior observation in uterine artery (72) . There are no previous reports of P 4 regulation of IDE or the ECE. Some evidence indicates that P 4 can increase NEP expression in human endometrium (73) and TTR in rat choroid plexus (67) . Similar to our observations with E 2 , the strongest effect of P 4 on A␤ clearance factors across paradigms was increased expression of IDE. Because E 2 and P 4 often exert interactive effects on tissues and both are present endogenously and typically coadministered in postmenopausal hormone therapy (HT), it is important to understand their combined effects. To address this issue, we compared delivery of P 4 in continuous vs. cyclic manners, alone and in combination with E 2 . Our data show that neural IDE mRNA expression in OVX rats is increased by treatment with E 2 , cyclic P 4 , and the combination of E 2 and cyclic P 4 . In the same animals, the lowest levels of soluble A␤ were observed in the E 2 and E 2 ϩcyclic P 4 groups. Notably, continuous P 4 delivered either alone or in combination with E 2 neither increased IDE mRNA expression nor reduced A␤ levels. One limitation of this model is the use of sc hormone delivery pellets, which can result in supraphysiological levels of hormones (74) . However, our findings of significant IDE regulation by E 2 and P 4 across three paradigms with different hormone delivery regimens argue that the observed relationships are significant.
The data indicate an inverse relationship between IDE expression and A␤ levels that is consistent with the possibility that regulation of IDE expression by E 2 and P 4 may contribute to their A␤-lowering actions. In addition, the results support conclusions of prior studies from our laboratory and others demonstrating that cyclic P 4 treatment is generally more beneficial than continuous P 4 treatment either alone or in combination with E 2 (22, 75, 76) . For example, choline acetyltransferase activity was observed to be higher in OVX female rats treated with E 2 with cyclic P 4 than with E 2 alone, but lowest in rats treated with E 2 and continuous P 4 (75) . In data particularly relevant to this study, cyclic but not continuous P 4 reduced A␤ accu-
FIG. 5.
Effects of long-term in vivo hormone treatments on levels of A␤ clearance factors. A, Representative agarose gel of RT-PCR products qualitatively shows changes in the levels of IDE, ACE, ECE2, and TTR mRNA across the following treatment groups (n ϭ 8/group): vehicletreated Sham OVX (Sham), vehicle-treated OVX (OVX), and OVX treated with continuous E 2 (OVXϩE 2 ), continuous P 4 (OVXϩP4 co ), cyclic P 4 (OVXϩP4 cy ), or continuous E 2 combined with either continuous P 4 (OVXϩE2ϩP4 co ) or cyclic P 4 (OVXϩE 2 ϩP4 cy ). B-E, Quantitative real-time PCR data show the mean (ϮSEM) expression levels compared with the Sham OVX control group (solid bar) for IDE, ACE, ECE2, and TTR mRNA, respectively. All data are normalized with corresponding ␤-actin values. Statistical significance is based on analysis of pooled raw data using the Tukey HSD. *, P Ͻ 0.01 relative to the vehicle-treated Sham OVX group. •, P Ͻ 0.01 relative to the OVX group.
Endocrinology, November 2012, 153(11):5467-5479 endo.endojournals.org 5475 mulation in 3xTg-AD mice, whereas continuous P 4 but not cyclic P 4 prevented the A␤-lowering action of E 2 (22) . The differential effects of continuous vs. cyclic P 4 may reflect broad differences in gene expression profiles that vary according to hormone regimens (76) . Unclear is whether delivery of E 2 in a cyclic manner may offer further benefits, although the near-maximal effects of the used continuous E 2 delivery relative to OVX alone suggests limited opportunity for improvement. The mechanism underlying the regulation of A␤-degrading enzymes by E 2 and P 4 is not well defined. Some evidence suggests roles of the estrogen receptors ER␣ and ER␤ in E 2 -mediated changes (54, 65, 67) . We show that the E 2 regulation of IDE mRNA is blocked by the antiestrogen ICI 182,780, implicating ER-dependent signaling.
We further demonstrate that both ER␣ and ER␤ may be important in the E 2 -mediated regulation of IDE because both ER␣ and ER␤ agonists up-regulated IDE transcript expression in a dose-dependent manner. E 2 could directly increase the IDE mRNA expression via classic genomic signaling in which ER bind to estrogen-response elements (ERE) on the target gene for transcriptional regulation. Consistent with this possibility, analysis of the promoter region of rat IDE gene using MatInspector (77) reveals four putative canonical ERE (GGTCAnnnTGACC). Alternatively, E 2 may increase IDE expression indirectly via activation of one or more of the cell-signaling pathways. For example, E 2 is known to activate phosphatidylinositol-3 kinase (78), which in turn is implicated in the insulindependent up-regulation of IDE (79) . The role of PR in Relative amounts of IDE protein levels were determined by densitometric scanning of Western blots from three independent experiments. E, Effect of OVX and short-term treatment of OVX rats with E 2 (OVXϩE 2 ) or P 4 (OVXϩP 4 ) on IDE protein levels is shown by a representative Western blot (upper panel) and quantification of Western blot data from all animals (n ϭ 7/group) (lower panel). Data are represented as a mean (ϮSEM) percentage of control values. Statistical significance is based on analysis of pooled raw data using the Tukey HSD. *, P Ͻ 0.01 relative to vehicle-treated control groups or Sham OVX group. •, P Ͻ 0.01 relative to the OVX group.
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Jayaraman et al. regulating IDE is unclear. Although the PR antagonists RU486 and Org 31710 inhibited P 4 regulation of TTR mRNA, the antagonists failed to block the P 4 -mediated increase in IDE mRNA levels in neuron culture, suggesting that neither of the two PR isoforms A and B mediates this P 4 response. Future work will determine whether the mechanism involves a nonclassical mediator of P 4 action (e.g. PR membrane component 1) or perhaps P 4 metabolites (e.g. allopregnanolone). Further investigation of the roles of ER and PR is required to completely understand the mechanism underlying the observed regulation of these A␤ clearance factors. Our study provides novel insight into the roles of individual and interactive effects of E 2 and P 4 in regulating A␤ by analyzing their effects on the expression of A␤ clearance factors. The most significant observation is that both E 2 and P 4 increase IDE mRNA expression in vitro and in vivo. This, taken together with the inverse relationship in vivo between IDE expression and A␤ levels, suggests another possible mechanism by which E 2 and P 4 can affect A␤ accumulation. Continued investigation of the interactions between E 2 and P 4 in regulating A␤ production and degradation is essential for optimizing hormone-based strategies for the prevention and/or treatment of AD. 
